These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 19755303)

  • 1. A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent:the SPIRIT II trial.
    Serruys PW; Ruygrok P; Neuzner J; Piek JJ; Seth A; Schofer JJ; Richardt G; Wiemer M; Carrié D; Thuesen L; Boone E; Miquel-Herbert K; Daemen J
    EuroIntervention; 2006 Nov; 2(3):286-94. PubMed ID: 19755303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized comparison of a durable polymer Everolimus-eluting stent with a bare metal coronary stent: The SPIRIT first trial.
    Serruys PW; Ong AT; Piek JJ; Neumann FJ; van der Giessen WJ; Wiemer M; Zeiher A; Grube E; Haase J; Thuesen L; Hamm C; Otto-Terlouw PC
    EuroIntervention; 2005 May; 1(1):58-65. PubMed ID: 19758878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
    Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
    Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One-year results of a durable polymer everolimus-eluting stent in de novo coronary narrowings (The SPIRIT FIRST Trial).
    Tsuchida K; Piek JJ; Neumann FJ; van der Giessen WJ; Wiemer M; Zeiher AM; Grube E; Haase J; Thuesen L; Hamm CW; Veldhof S; Dorange C; Serruys PW
    EuroIntervention; 2005 Nov; 1(3):266-72. PubMed ID: 19758915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design.
    Diletti R; Serruys PW; Farooq V; Sudhir K; Dorange C; Miquel-Hebert K; Veldhof S; Rapoza R; Onuma Y; Garcia-Garcia HM; Chevalier B
    Am Heart J; 2012 Nov; 164(5):654-63. PubMed ID: 23137495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Five-year long-term clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery disease: the SPIRIT II trial.
    Onuma Y; Miquel-Hebert K; Serruys PW;
    EuroIntervention; 2013 Jan; 8(9):1047-51. PubMed ID: 23339811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One year clinical follow-up of the XIENCE V Everolimus-eluting stent system in the treatment of patients with de novo native coronary artery lesions: the SPIRIT II study.
    Ruygrok PN; Desaga M; Van Den Branden F; Rasmussen K; Suryapranata H; Dorange C; Veldhof S; Serruys PW
    EuroIntervention; 2007 Nov; 3(3):315-20. PubMed ID: 19737711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SPIRIT IV trial design: a large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease.
    Nikolsky E; Lansky AJ; Sudhir K; Doostzadeh J; Cutlip DE; Piana R; Su X; White R; Simonton CA; Stone GW
    Am Heart J; 2009 Oct; 158(4):520-526.e2. PubMed ID: 19781409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three-year results of safety and efficacy of the everolimus-eluting coronary stent in women (from the SPIRIT III randomized clinical trial).
    Ng VG; Lansky AJ; Hermiller JB; Farhat N; Applegate RJ; Yaqub M; Sood P; Su X; Simonton CA; Sudhir K; Stone GW
    Am J Cardiol; 2011 Mar; 107(6):841-8. PubMed ID: 21255760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential clinical responses to everolimus-eluting and Paclitaxel-eluting coronary stents in patients with and without diabetes mellitus.
    Stone GW; Kedhi E; Kereiakes DJ; Parise H; Fahy M; Serruys PW; Smits PC
    Circulation; 2011 Aug; 124(8):893-900. PubMed ID: 21824922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differentiated analysis of an everolimus-eluting stent and a paclitaxel-eluting stent among higher risk subgroups for restenosis: results from the SPIRIT II trial.
    Khattab AA; Richardt G; Verin V; Kelbaek H; Macaya C; Berland J; Miquel-Hebert K; Dorange C; Serruys PW
    EuroIntervention; 2008 Mar; 3(5):566-73. PubMed ID: 19608482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of paclitaxel-eluting stent implantation in patients with stenosis of the left anterior descending coronary artery.
    Dangas G; Ellis SG; Shlofmitz R; Katz S; Fish D; Martin S; Mehran R; Russell ME; Stone GW;
    J Am Coll Cardiol; 2005 Apr; 45(8):1186-92. PubMed ID: 15837247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Everolimus-eluting stents in patients undergoing percutaneous coronary intervention: final 3-year results of the Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With de Novo Native Coronary Artery Lesions trial.
    Brener SJ; Kereiakes DJ; Simonton CA; Rizvi A; Newman W; Mastali K; Wang JC; Caputo R; Smith RS; Ying SW; Cutlip DE; Stone GW
    Am Heart J; 2013 Dec; 166(6):1035-42. PubMed ID: 24268218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial.
    Stone GW; Ellis SG; Cox DA; Hermiller J; O'Shaughnessy C; Mann JT; Turco M; Caputo R; Bergin P; Greenberg J; Popma JJ; Russell ME;
    Circulation; 2004 Apr; 109(16):1942-7. PubMed ID: 15078803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomised comparison of Nobori, biolimus A9-eluting coronary stent with a Taxus(R), paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the Nobori 1 trial.
    Chevalier B; Serruys PW; Silber S; Garcia E; Suryapranata H; Hauptmann K; Wijns W; Schuler G; Fath-Ordoubadi F; Worthley S; Thuesen L; Meredith I; Bressers M; Nagai H; Paunovic D
    EuroIntervention; 2007 Feb; 2(4):426-34. PubMed ID: 19755281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes in real-world patients with acute myocardial infarction receiving XIENCE V® everolimus-eluting stents: one-year results from the XIENCE V USA study.
    Sudhir K; Hermiller JB; Naidu SS; Henry TD; Mao VW; Zhao W; Ferguson JM; Wang J; Jonnavithula L; Simonton CA; Rutledge DR; Krucoff MW;
    Catheter Cardiovasc Interv; 2013 Oct; 82(4):E385-94. PubMed ID: 23172848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter randomized trial comparing amphilimus- with paclitaxel-eluting stents in de novo native coronary artery lesions.
    Carrié D; Berland J; Verheye S; Hauptmann KE; Vrolix M; Violini R; Dibie A; Berti S; Maupas E; Antoniucci D; Schofer J
    J Am Coll Cardiol; 2012 Apr; 59(15):1371-6. PubMed ID: 22284328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective randomised study using optical coherence tomography to assess endothelial coverage and neointimal proliferation at 6-months after implantation of a coronary everolimus-eluting stent compared with a bare metal stent postdilated with a paclitaxel-eluting balloon (OCTOPUS Trial): rationale, design and methods.
    Poerner TC; Otto S; Gassdorf J; Janiak F; Danzer C; Ferrari M; Figulla HR
    EuroIntervention; 2011 May; 7 Suppl K():K93-9. PubMed ID: 22027737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two-year results of a durable polymer everolimus-eluting stent in de novo coronary artery stenosis (The SPIRIT FIRST Trial).
    Beijk MA; Neumann FJ; Wiemer M; Grube E; Haase J; Thuesen L; Hamm C; Veldhof S; Dorange C; Serruys PW; Piek JJ
    EuroIntervention; 2007 Aug; 3(2):206-12. PubMed ID: 19758939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized comparison of the Endeavor zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial.
    Leon MB; Mauri L; Popma JJ; Cutlip DE; Nikolsky E; O'Shaughnessy C; Overlie PA; McLaurin BT; Solomon SL; Douglas JS; Ball MW; Caputo RP; Jain A; Tolleson TR; Reen BM; Kirtane AJ; Fitzgerald PJ; Thompson K; Kandzari DE;
    J Am Coll Cardiol; 2010 Feb; 55(6):543-54. PubMed ID: 20152559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.